Literature DB >> 28979765

MicroRNAs in the development and neoplasia of the mammary gland.

Manoj Kumar Jena1.   

Abstract

Study on the role of microRNAs (miRs) as regulators of gene expression through posttranscriptional gene silencing is currently gaining much interest,due to their wide involvement in different physiological processes. Understanding mammary gland development, lactation, and neoplasia in relation to miRs is essential. miR expression profiling of the mammary gland from different species in various developmental stages shows their role as critical regulators of development. miRs such as miR-126, miR-150, and miR-145 have been shown to be involved in lipid metabolism during lactation. In addition, lactogenic hormones influence miR expression as evidenced by overexpression of miR-148a in cow mammary epithelial cells, leading to enhanced lactation. Similarly, the miR-29 family modulates lactation-related gene expression by regulating DNA methylation of their promoters. Besides their role in development, lactation and involution, miRs are responsible for breast cancer development. Perturbed estrogen (E2) signaling is one of the major causes of breast cancer. Increased E2 levels cause altered expression of ERα, and ERα-miR cross-talk promotes tumour progression. miRs, such as miR-206, miR-34a, miR-17-5p, and miR-125 a/b are found to be tumour suppressors; whereas miR-21, miR-10B, and miR-155 are oncogenes. Oncogenic miRs like miR-21, miR-221, and miR-210 are overexpressed in triple negative breast cancer cases which can be diagnostic biomarker for this subtype of cancer.  This review focuses on the recent findings concerning the role of miRs in developmental stages of the mammary gland (mainly lactation and involution stages) and their involvement in breast cancer progression. Further studies in this area will help us to understand the molecular details of mammary gland biology, as well as miRs that could be therapeutic targets of breast cancer.

Entities:  

Keywords:  Mammary gland; development; lactation; miRNA; neoplasia

Year:  2017        PMID: 28979765      PMCID: PMC5609084          DOI: 10.12688/f1000research.12005.2

Source DB:  PubMed          Journal:  F1000Res        ISSN: 2046-1402


Introduction

MicroRNAs (miRs) are small, endogenous noncoding RNAs that regulate gene expression post-transcription, by degrading target mRNA or repressing translation. They are hardy in nature, being resistant to RNAse degradation, acidic pH, and repeated freezing and thawing, and are stable at room temperature [1]. Matured miRs integrate into the RNA - induced silencing complex (RISC) and direct it to target mRNAs through partial sequence complementarity. miRs down regulate the target gene expression by translation repression (48% through RISC complex), or mRNA degradation (29%), or by both phenomena (23%) [2]. In addition to their involvement in many other physiological processes, they play crucial roles in mammary gland development and lactation, and their deregulation can lead to breast cancer [3]. This review provides an overview on the recent findings concerning the role of miRs in the developmental stages of the mammary gland and breast cancer progression.

miRs in mammary glands

The study of miRs in mammary gland development is essential, as miRs in milk are derived from the mammary gland and can be a biomarker of a healthy lactating gland, as well as protecting infants and promoting their development [4]. miRs in milk during lactation are putative markers of activities in mammary gland and act as functional signals for proper growth and development of the young. The highly abundant miRs in milk during lactation cycle are miR-191, 184, 181, 148, 375, and miRs of let-7 family (7f, 7a and 7i) as evidenced from studies in the marsupial tammar wallaby [5]. Comparative analysis of the miRNome of bovine milk, mammary tissue, milk fat, and whey revealed 188 miRs in common, with some novel miRs discovered [6]. The miR signature of milk fat was similar to that of mammary gland tissue miRs. Functional studies of highly expressed miRs in those fractions indicated their role as regulators of mammary gland functions contributing to healthy milk production [6].

miRs controlling lactation

It was observed that miR-126 plays a role in mammary epithelial cells (MECs) by modulating lipid synthesis [7]. FASN (fatty acid synthase) gene expression is increased when miR-126-3p is inhibited, suggesting its involvement in lipid metabolism in the mammary gland. In addition, estradiol and progesterone enhanced lipid synthesis by downregulating the levels of miR-126-3p [7]. Similarly, miR-150 hampers lipogenesis in MECs and reduces secretory activity [8], while miR-145 facilitates milk fat synthesis in lactating goats by targeting the gene INSIG1 (insulin induced gene 1) [9]. The role that miRs play as regulators of lipogenesis was confirmed by overexpression studies, which showed that there was more synthesis of fat droplets, accumulating triacylglycerols, and a higher proportion of unsaturated fatty acids in lactating MECs. For instance, miR-24 was found to be expressed at a much higher level during peak lactation in goats and affects triacylglycerol content, unsaturated fatty acid concentration, and expression of target genes such as FASN, SREBF1 (sterol regulatory element binding transcription factor1), SCD (stearoyl-CoA desaturase), GPAM (glycerol-3-phosphate acyltransferase; mitochondrial), and ACACA (acetyl-CoA carboxylase) [10]. miR expression in MECs is regulated by lactogenic hormones (dexamethasone, insulin, and prolactin) as evidenced by an increased miR-148a level in bovine MECs, which is probably associated with increased milk production during lactation in cows [11]. The miR-29 family affects lactation by regulating the DNA methylation of target genes DNMT3A and DNMT3B (DNA (cytosine-5)-methyltransferase 3A and 3B) in MECs of dairy cows [12]. Moreover, inhibition of the miR-29 family resulted in hypermethylation of promoters of lactation–related genes leading to decreased secretion of triglycerides, proteins, and lactose by the epithelial cells. miR-486 facilitates lactation by downregulating PTEN (phosphatase and tensin homolog) target gene. Downregulation of this gene affects the expression of downstream genes, such as AKT, mTOR and β-casein, which have crucial roles in mammary gland development and lactation [13]. Additionally, diet restriction has been shown to affect the miRNome of lactating mammary glands, indicating the role of miRs in regulating milk composition [14]. Lin et al. (2013) [15] observed group of miRs (such as miR-23a, 27b, 103, and 200a) affect milk fat synthesis with synergistic action. miR profiling of lactating and nonlactating bovine mammary gland revealed miR-125b, 181a, and 199b expression level reduced in non-lactation period; whereas miR-141, 484, and 500 expression level was higher in lactation period [16]. Highly expressed miRs such as let-7f-5p is found to target many genes involved in protein, carbohydrate, and triglyceride synthesis. The human milk enriched miR such as miR-22-3P regulates development and differentiation of T-lymphocytes. The miR-181a-5p and miR-182-5p have crucial role in immune cell differentiation, miR-375 is required for glucose homeostasis, and miR-148a-3p is a tumour suppressor and involved in liver development [17].

miRs controlling involution and breast cancer

Identification and characterization of miRs involved in breast cancer will facilitate targeting miRs for possible therapy. Improper involution possibly contributes towards tumour development [18]. miR-424(322)/503 regulates mammary involution in humans by targeting BCL-2 (B-cell lymphoma 2; anti-apoptotic) and IGF1R (insulin like growth factor-1-receptor) genes. The loss of this miR leads to malignancy and nonresponse to chemotherapy, demonstrating its role as a tumour suppressor [18]. By contrast, some miRs, such as miR-660-5p, promote tumour development and metastasis, and the level of miR-660-5p was found to be increased in MCF7 breast cancer cell lines [19]. This miR’s tumour promoting activity was confirmed by observation of reduced invasion of MCF7 cells at reduced miR-660-5p levels. One of the major causes of breast cancer is disturbed estrogen signaling, where the altered expression of estrogen receptor α (ERα) and its cross-talk with the related miR culminates in neoplasia [20]. Studies on the effect of E2 on the expression pattern of miRs in MCF7 and ZR75 cell lines revealed 172 miRs that were up or downregulated. Notable miRs are miR-206, miR-34a, miR-17-5p, and miR-125 a/b, which act as tumour suppressors, and miR-21, miR-10B, and miR-155, which act as oncogenes [21]. Another study using an ACI rat model for the effect of E2 on the miR signature showed 33 dysregulated miRs [22]. Additionally, the use of ellagic acid (natural phenol antioxidant) reversed the dysregulation of miR-206, miR-182, miR-375, miR-127, miR-183, and miR-122, subsequently modulating the target proteins ERα, RASD1, cyclin D1, FoxO1, FoxO3a, Bcl-w, Bcl-2 and cyclin G118 [22]. Furthermore, overexpression of the tumour suppressing miR-133a in MCF-7 and MDA-MB-231 cells suppressed phosphorylated Akt (p-Akt) protein and inhibited p-Akt nuclear translocation, and this miR also regulates the cell cycle of cancerous cells by targeting the EGFR (epidermal growth factor receptor) gene [23]. miR-206 is found to play a crucial role in BRCA1 (Breast CAncer susceptibility gene; tumour suppressor) depleted mouse mammary gland [24]. Overexpression of miR-206 showed no effect on lactation, but did have a role in tissue remodeling through increasing fat tissue and reducing branching morphogenesis. There may be a possibility of increased miR-206 levels due to BRCA1 loss, culminating in mammary gland remodeling and tumour development [24]. miR-184 is found to be a tumour suppressor by regulating the number of genes in the PI3K/AKT/mTOR pathway, as observed by miR profiling of the pubertal mouse mammary gland [25]. This pathway is important in mammary gland development and lactation [26]. miR-184 is only expressed in epithelial cells, and the level increases during differentiation of cells from terminal end bud into ductal epithelial cells [25]. The miR 126/126* pair is observed to repress the recruitment of mesenchymal stem cells and inflammatory monocytes into the tumour stroma, thus inhibiting breast cancer metastasis [27]. Urinary miR detection of overexpressed miR-155, and lowered expression of miR – 21, 125b, and 451 can act as non-invasive biomarker for breast cancer detection [28]. Chan et al. (2013) [29] identified the miR signature (miR-1, 92a, 133a, and 133b) in serum which can be used as biomarkers for breast cancer detection as a noninvasive diagnostic strategy. Similar study by Mar-Aguilar et al., (2013) [30] identified miR-145, 155, and 382 as potential biomarker for breast cancer detection. Deregulated expression of miR-17, 34a, 155 ,and 373 and their concentration in serum as cell-free miR probably connects to the progression and metastasis of breast cancer [31]. Exosomes are cell - derived small vesicles (40 – 100 nm) containing mRNA, protein, miR etc. They are crucial mediator of inter cellular signaling during cancer development. Exosomes derived from cancer associated fibroblasts in breast cancer have 3 miRs such as miR-21, -143, and -378e which promote stemness, epithelial-mesenchymal transition, and anchorage-independent cell growth, thus accelerating oncogenic signaling in breast cancer cells [32]. The exosomes released from cancer cells of breast cancer patients induce the non-tumorigenic epithelial cells to form tumors with the help of dicer endonuclease [33]. Triple negative breast cancer (TNBC) is a subtype of breast cancer where the cancer cells lack the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) [34]. Out of total breast cancer cases 10 – 20% are TNBC cases and various studies showed the expression of specific miR pattern in these cases which can act as biomarker for cancer diagnosis [30, 35, 36]. A recent study on paired sera and tissue samples of TNBC patients in India revealed overexpression of 3 oncogenic miRs (miR – 21, 221, and 210) and down regulation of miR – 195 and miR – 145 as compared to that of triple positive breast cancer cases. The TNBC cases were found to be highly prevalent (73.9%) in pre-maunopausal (<35 yr) women and the miR let7a was overexpressed although it is known as a tumour suppressor. Increased serum level of exosomal miR-373 can also be a marker for TNBC cases [37]. The study of TNBCs with lymphnode metastases showed association of 27 miRs with metastatic capability. This study observed 71 differentially expressed miRs in TNBCs including miR-200 family and miR-17-92 oncogenic cluster [38].

Conclusions

miRs have been shown to be one of the major regulators of mammary gland development and neoplasia. miRNome studies of mammary gland in different developmental stages and cancerous tissues will elucidate biomarkers for early cancer diagnosis, and may be used as therapeutic targets. Future studies focusing on the cross-talk between miRs and target genes with the signaling pathways involved in development and neoplasia of mammary gland will open the door to understand mammary gland biology and oncogenesis in molecular detail. All the suggestions made by the referee are sufficient and the paper is suggested to be indexed in F1000Research. I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. Review article on “MicroRNAs in the development and neoplasia of the mammary gland” submitted by M.K. Jena deals with how various microRNAs that regulate gene expression through post transcriptional gene silencing are important during development and progression as well as prognosis of cancer of the mammary gland in women. Though I understand it is a mini-review but it has not been written in a very focused and systematic way. There are huge numbers of publications in this field, particularly the role of mRNA in breast carcinogenesis. However, the author cites only 22 references in this article which is highly inadequate to justify the review on the role of miRNA in mammary gland development and carcinogenesis. Author must consult recently published literatures including a recent paper by Thakur et al. (2016) [1] and many of the references therein. There are a lot of sweeping comments have been made which indicates that the author has nothing much to do with cancer specialty.  The comments in abstract say ‘miRs are responsible for breast cancer development’. It is not straight forward and clear that miRNA are responsible of breast cancer development. They may be associated with but not directly correlated with cancer development. Similar sweeping comments are many in the text and these need to be addressed properly and the manuscript needs to be elaborative and focused. The presentation of the review article should be made with proper sub-headings on mammary gland development, lactation and carcinogenesis. In summary, I suggest that the article can be considered for indexing only after satisfactory revision. I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. All the suggestions made by the referee has been complied in the second version of this article. With this review, the author provide a concise literature summary of microRNAs in the development and neoplasia of the mammary gland. For the most part the review is complete and informative. To further improve the quality, the author is advised to address these minor points: Exosomes secreted by different cells of mammary gland carry microRNA. It has been demonstrated that cancer-associated fibroblasts release exosomal microRNA that induce aggressiveness in breast cancer cells (e.g. Donnarumma et al. (2017) [1]). At the same time, the microRNA present in the exosomes secreted by the cancer cells also play a critical role in the pathogenesis of breast cancer (e.g. Melo et al. (2014) [2]). Hence, the authors might consider to include these information. The beginning sentence under “miRs in mammary gland” heading needs to be restructured. The presence of miRNA in milk and the role of miRNA in mammary development should be mentioned separately. In the abstract, the sentence “Further studies in this area will help us understand ……” should be “Further studies in this area will help us to understand ……”). I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. To be incorporated in the heading "miRs controlling involution and breast cancer": Exosomes are cell - derived small vesicles (40 - 100 nm) containing mRNA, protein, miR etc. They are crucial mediator of inter cellular signaling during cancer development. Exosomes derived from cancer associated fibroblasts in breast cancer have 3 miRs such as miR-21, -143, and -378e which promote stemness, epithelial-mesenchymal transition, and anchorage-independent cell growth, thus accelerating oncogenic signaling in breast cancer cells (Donnarumma et al., 2017). The exosomes released from cancer cells of breast cancer patients induce the non-tumorigenic epithelial cells to form tumors with the help of dicer endonuclease (Melo et al., 2014). The beginning sentence under “miRs in mammary gland” will be restructured. The presence of miRNA in milk and the role of miRNA in mammary development will be separated. In the abstract, the sentence “Further studies in this area will help us understand ……” will be rectified as “Further studies in this area will help us to understand ……”. The review entitled "MicroRNAs in the development and neoplasia of the mammary gland" has briefly presented recent studies in the relevant studies in mammary gland microRNAs field. This kind of review is very good for scientists to update their knowledge without reading informative reviews. However, minor comments are below to make the review suitable for indexing: Introduction: More information is needed to understand the mechanism of microRNA roles in the mammary gland. miRs in mammary gland: Along with Alsaweed et al. study, Modepalli et al. (2014, BMC Genomics) has provided evidence that mammary gland is the main source of microRNAs in milk. Therefore, milk microRNAs are not considered as nutrients as stated, so better to not use "whether they are only simple nutrients". Examples about the milk microRNAs are important as the mammary gland is synthesized and secreted milk. miRs controlling lactation: Highly expressed microRNAs in milk/mammary gland have different roles in synthesize various milk nutrient contents such as triacylglycerols and lactose, so the role of highly expressed microRNAs must be linked to related functions (Alsaweed et al 2016, PLoS ONE and IJMS). Li et al. (2012, BMC Genomics) has presented very important aspects of the microRNAs and lactation performance. miRs controlling involution and breast cancer: Zhang et al. (2013, Nature Cell Biology) has provided breast cancer inhibits progression by microRNAs expression roles, so it must be considered in this review. I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. Introduction Mechanism of action to be incorporated: Matured miRs integrate into the RNA - induced silencing complex (RISC) and direct it to target mRNAs through partial sequence complementarity. miRs down regulate the target gene expression by translation repression (48 % through RISC complex), or mRNA degradation (29 %), or by both phenomena (23 %). (Jin and Xiao, 2015). miRs in mammary glands To be removed: The role of miRs........still disputed. To be incorporated: miRs in milk during lactation are putative markers of activities in mammary gland and act as functional signals for proper growth and development of the young. The highly abundant miRs in milk during lactation cycle are miR-191, 184, 181, 148, 375, and miRs of let-7 family (7f, 7a and 7i) as evidenced from studies in the marsupial tammar wallaby (Modepalli et al., 2014). miRs controlling lactation To be incorporated: Lin et al (2013) observed group of miRs (such as miR-23a, 27b, 103, and 200a) affect milk fat synthesis with synergistic action. miR profiling of lactating and nonlactating bovine mammary gland revealed miR-125b, 181a, and 199b expression level reduced in non-lactation period; whereas miR-141, 484, and 500 expression level was higher in lactation period. (Li et al., 2012). Highly expressed miRs such as let-7f-5p is found to target many genes involved in protein, carbohydrate, and triglyceride synthesis. The human milk enriched miR such as miR-22-3P regulates development and differentiation of T-lymphocytes. The miR-181a-5p and miR-182-5p have crucial role in immune cell differentiation, miR-375 is required for glucose homeostasis, and miR-148a-3p is a tumour suppressor and involved in liver development (Alsaweed et al., 2016). miRs controlling involution and breast cancer To be incorporated: The miR 126/126* pair is observed to repress the recruitment of mesenchymal stem cells and inflammatory monocytes into the tumour stroma, thus inhibiting breast cancer metastasis (Zhang et al., 2013).
  38 in total

1.  Identification of circulating microRNA signatures for breast cancer detection.

Authors:  Maurice Chan; Chiew Suan Liaw; Shen Mo Ji; Hwee Huang Tan; Chow Yin Wong; Aye Aye Thike; Puay Hoon Tan; Gay Hui Ho; Ann Siew-Gek Lee
Journal:  Clin Cancer Res       Date:  2013-06-24       Impact factor: 12.531

2.  Inhibition of miR-660-5p expression suppresses tumor development and metastasis in human breast cancer.

Authors:  Y Shen; Y F Ye; L W Ruan; L Bao; M W Wu; Y Zhou
Journal:  Genet Mol Res       Date:  2017-02-23

3.  Serum circulating microRNA profiling for identification of potential breast cancer biomarkers.

Authors:  Fermín Mar-Aguilar; Jorge A Mendoza-Ramírez; Ismael Malagón-Santiago; Perla K Espino-Silva; Sandra K Santuario-Facio; Pablo Ruiz-Flores; Cristina Rodríguez-Padilla; Diana Reséndez-Pérez
Journal:  Dis Markers       Date:  2013       Impact factor: 3.434

4.  Identification of conserved microRNAs in peripheral blood from giant panda: expression of mammary gland-related microRNAs during late pregnancy and early lactation.

Authors:  C D Wang; K Long; L Jin; S Huang; D H Li; X P Ma; M Wei; Y Gu; J D Ma; H Zhang
Journal:  Genet Mol Res       Date:  2015-11-13

5.  microRNA-133a regulates the cell cycle and proliferation of breast cancer cells by targeting epidermal growth factor receptor through the EGFR/Akt signaling pathway.

Authors:  Wenjing Cui; Shuai Zhang; Changliang Shan; Li Zhou; Zhemin Zhou
Journal:  FEBS J       Date:  2013-07-10       Impact factor: 5.542

6.  MiR-486 regulates lactation and targets the PTEN gene in cow mammary glands.

Authors:  Dan Li; Xuejiao Xie; Jie Wang; Yanjie Bian; Qingzhang Li; Xuejun Gao; Chunmei Wang
Journal:  PLoS One       Date:  2015-03-04       Impact factor: 3.240

7.  Differential temporal expression of milk miRNA during the lactation cycle of the marsupial tammar wallaby (Macropus eugenii).

Authors:  Vengamanaidu Modepalli; Amit Kumar; Lyn A Hinds; Julie A Sharp; Kevin R Nicholas; Christophe Lefevre
Journal:  BMC Genomics       Date:  2014-11-23       Impact factor: 3.969

8.  Comparative Analysis of the miRNome of Bovine Milk Fat, Whey and Cells.

Authors:  Ran Li; Pier-Luc Dudemaine; Xin Zhao; Chuzhao Lei; Eveline Mengwi Ibeagha-Awemu
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

9.  Identification of Specific miRNA Signature in Paired Sera and Tissue Samples of Indian Women with Triple Negative Breast Cancer.

Authors:  Seema Thakur; Rajesh K Grover; Sanjay Gupta; Ajay K Yadav; Bhudev C Das
Journal:  PLoS One       Date:  2016-07-12       Impact factor: 3.240

10.  Cancer-associated fibroblasts release exosomal microRNAs that dictate an aggressive phenotype in breast cancer.

Authors:  Elvira Donnarumma; Danilo Fiore; Martina Nappa; Giuseppina Roscigno; Assunta Adamo; Margherita Iaboni; Valentina Russo; Alessandra Affinito; Ilaria Puoti; Cristina Quintavalle; Anna Rienzo; Salvatore Piscuoglio; Renato Thomas; Gerolama Condorelli
Journal:  Oncotarget       Date:  2017-03-21
View more
  4 in total

1.  Cloning and characterization of Bubaline mammary miRNAs: An in silico approach.

Authors:  Krishnadeo Ankush Khade; Manjit Panigrahi; Sheikh Firdous Ahmad; Anuj Chauhan; Pushpendra Kumar; Bharat Bhushan
Journal:  Mol Biol Rep       Date:  2019-02-20       Impact factor: 2.316

2.  LncRNA SNHG6/miR-125b-5p/BMPR1B Axis: A New Therapeutic Target for Triple-Negative Breast Cancer.

Authors:  Yufei Lv; Xiaohong Lv; Huike Yang; Xiuying Qi; Xiangchen Wang; Chao Li; Xiaochen Shang; Hongmin Guo; Jianguo Zhang; Yafang Zhang
Journal:  Front Oncol       Date:  2021-05-07       Impact factor: 6.244

3.  MicroRNAs as biomarkers for breast cancer.

Authors:  Duran Canatan; Yonca Sönmez; Özlem Yılmaz; Abdullah Çim; Hasan Şenol Coşkun; Sema Sezgin Göksu; Selda Ucar; Mehmet Rıfkı Aktekin
Journal:  Acta Biomed       Date:  2021-05-12

4.  MicroRNA-384 inhibits the progression of breast cancer by targeting ACVR1.

Authors:  Yongxia Wang; Zheying Zhang; Jianqiang Wang
Journal:  Oncol Rep       Date:  2018-04-20       Impact factor: 3.906

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.